Story perspectives

Mellencamp Denied GLP-1 as Stage-4 Melanoma Persists

4/25/2026

Summary

Mellencamp Denied GLP-1

Teddi Mellencamp said her doctor refused her request for GLP-1 medication to treat weight gain, noting she was diagnosed with stage 2 melanoma in 2022.
By April 2025 she had melanoma that spread to her brain and lungs, reaching stage 4, and although doctors reported no detectable cancer in October 2025 she remained stage 4 and would receive immunotherapy.
Dolores Catania said she will start GLP-1 treatment on April 24, 2026 and suggested Mellencamp could get the drug from friends.

Summary

Mellencamp Posts Scan

Mellencamp posted a February 9 Instagram photo of electrodes on her head before a brain scan.
She thanked doctors, nurses, family and fans for support during treatment.
Mellencamp urged followers to trust instincts and get checked for health issues.
She shaved her head in February 2025 to prepare for brain tumor surgery.
She, a health and wellness coach, framed her cancer battle as a message about living fully despite illness.

Summary

Mellencamp Cancer Reveal

Teddi Mellencamp (44), founder of the wellness brand All In with Teddi, appeared on the April 23, 2026 Two T’s in a Pod episode co-hosted by Real Housewives of New Jersey star Dolores Catania.
During the interview she said she is a health and wellness coach who is “dying of cancer.”
A neutral article published April 24, 2026 listed a reliability score of 36.71 and noted the clash between the celebrity and medical topics.

1 of 3

Mellencamp Denied GLP-1

Teddi Mellencamp said her doctor refused her request for GLP-1 medication to treat weight gain, noting she was diagnosed with stage 2 melanoma in 2022.
By April 2025 she had melanoma that spread to her brain and lungs, reaching stage 4, and although doctors reported no detectable cancer in October 2025 she remained stage 4 and would receive immunotherapy.
Dolores Catania said she will start GLP-1 treatment on April 24, 2026 and suggested Mellencamp could get the drug from friends.

1 / 3